Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.

Liu, Rong; Yuan, Ying; Sen, Suman; Yang, Xin; Jiang, Qi; Li, Xiaoyun Nicole; Lu, Chengxing Cindy; Göneng, Mithat; Tian, Hong; Zhou, Heng; Lin, Ruitao; Marchenko, Olga

Liu, Rong; Yuan, Ying; Sen, Suman; Yang, Xin; Jiang, Qi; Li, Xiaoyun Nicole; Lu, Chengxing Cindy; Göneng, Mithat; Tian, Hong; Zhou, Heng; Lin, Ruitao; Marchenko, Olga.

Afiliación

Liu R; Bristol-Myers Squibb, Berkeley Heights, NJ 07922.
Yuan Y; The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Sen S; Novartis, East Hanover, NJ 07936.
Yang X; Novartis, East Hanover, NJ 07936.
Jiang Q; Seattle Genetics, Bothell, WA 98021.
Li XN; Merck & Co., Inc., Kenilworth, NJ 07033.
Lu CC; AstraZeneca, Gaithersburg, MD 20878.
Göneng M; Memorial Sloan Kettering Cancer Center, New York, NY 10022.
Tian H; BeiGene, Ridgefield Park, NJ 07660.
Zhou H; Merck & Co., Inc., Kenilworth, NJ 07033.
Lin R; The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Marchenko O; Bayer, Whippany, NJ 07981.

Stat Biopharm Res ; 14(3): 270-282, 2022.

Article en En | MEDLINE | ID: mdl-37275462

Palabras clave

Clinical trial; Dose finding; Drug combination; Maximum tolerated dose; Toxicity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Stat Biopharm Res Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google